Document is current

Article History

First Online: 15 September 2020

Declarations

:

: JC: designed and conceived the study, analyzed the data, and wrote the original version; YX: conceived the study and developed the BP-ANN model; ZR: designed and conceived the study and performed the pharmacokinetics analysis; HL, BJ, RS, DY, and YH conceived the study. All authors were involved in reviewing the manuscript and approved the final version.

: This study was supported by the National Major Science and Technology projects of China (No. 2020ZX09201022). This study was funded by Jiangsu Aosaikang Pharmaceutical Co., Ltd.

: All authors (JC, YX, HL, BJ, RS, DY, YH, and ZR) report no conflicts of interest in this work.

: The protocol and amendment of the study were reviewed and approved by the Human Subject Research Ethics Committee of the Second Affiliated Hospital of Zhejiang University School of Medicine (Hangzhou, Zhejiang, China). The ethics approval number is 2018–672. This study was registered at (CTR20191164). The study was conducted at the Phase I Clinical Trials Unit (the Second Affiliated Hospital of Zhejiang University School of Medicine) in accordance with Good Clinical Practices and the ethical principles enunciated in the amended Declaration of Helsinki (revised version of Fortaleza, 2013). Documented written informed consent was obtained from each subject before any protocol-related investigations or procedures.

: Documented written informed consent was obtained from each subject before any protocol-related investigations or procedures.

: Not applicable.

: Not applicable.

: Not applicable.